Shanghai Universal Biotech Co.,Ltd. Stock

Equities

301166

CNE100005709

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-04-28 EDT 5-day change 1st Jan Change
29.7 CNY +2.13% Intraday chart for Shanghai Universal Biotech Co.,Ltd. +7.41% -22.70%

Financials

Sales 2022 1.2B 165M 226M Sales 2023 1.23B 170M 231M Capitalization 3.33B 460M 629M
Net income 2022 106M 14.66M 20.01M Net income 2023 40M 5.53M 7.55M EV / Sales 2022 1.99 x
Net cash position 2022 1.58B 219M 298M Net cash position 2023 * - 0 0 EV / Sales 2023 2.72 x
P/E ratio 2022
37.2 x
P/E ratio 2023
81.7 x
Employees 688
Yield 2022
1.97%
Yield 2023
-
Free-Float 30.51%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shanghai Universal Biotech Co.,Ltd.'s Equity Buyback Plan announced on March 2, 2024. CI
Shanghai Universal Biotech Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Shanghai Universal Biotech Co.,Ltd. authorizes a Buyback Plan. CI
Sengenics Corporation LLC Enters into Sales Distribution and Services Agreement with Shanghai Universal Biotech Co., Ltd CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Universal Biotech Co.,Ltd. Announces Final Dividend for 2022, Payable on 29 May 2023 CI
Shanghai Universal Biotech Approves Final Cash Dividend for 2022 CI
Shanghai Universal Biotech Co.,Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+2.13%
1 week+7.41%
Current month-1.46%
1 month-0.93%
3 months-9.31%
6 months-27.53%
Current year-22.70%
More quotes
1 week
27.63
Extreme 27.63
29.88
1 month
26.60
Extreme 26.6
31.88
Current year
22.81
Extreme 22.81
38.93
1 year
22.81
Extreme 22.81
50.39
3 years
22.81
Extreme 22.81
136.00
5 years
22.81
Extreme 22.81
136.00
10 years
22.81
Extreme 22.81
136.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 04-09-30
Director of Finance/CFO 44 19-08-31
Chief Operating Officer 44 10-10-31
Members of the board TitleAgeSince
Director/Board Member 66 20-04-15
Director/Board Member 46 18-10-31
Director/Board Member 38 15-10-31
More insiders
Date Price Change Volume
24-04-28 29.7 +2.13% 789 183
24-04-26 29.08 +1.01% 447,700
24-04-25 28.79 +1.37% 414,894
24-04-24 28.4 +1.61% 370,600
24-04-23 27.95 +0.29% 380,394

End-of-day quote Shenzhen S.E., April 28, 2024

More quotes
Shanghai Universal Biotech Co Ltd is a China-based company mainly engaged in the supply of life science reagent products. The Company is also engaged in the supply of life science instruments and consumables and comprehensive technical services. The products supplied by the Company are mainly third-party brand products, supplemented by independent brand products. The life science reagents mainly include immunological reagents based on antibodies and antibody related reagents, as well as molecular biology reagents, cell biology reagents and biochemical reagents. The life science instruments and consumables include detection and analysis and sample preparation. The comprehensive technical services include experimental services, technical support services and other services.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 301166 Stock